By now you've heard of CRISPR, the transformative gene editing tool.
Tessera therapeutics has invented a tool for gene writing... Giving promise to entirely new disease therapies and prevention - at the genetic level. Noubar Afayen, Moderna's Chairman and Flagship Pioneering CEO, co-founded Tessera with Jake Rubens and Flagship Partner Geoffrey von Maltzahn. They recently announced a series C raise - of over 300 million dollars. Von Malzahn is on Bloomberg's list of 50 ones to watch. He's already co-founded companies that have achieved over 10 billion in market cap. Bloomberg's Janet Wu sat down with him at Flagship Pioneering in Cambridge - to explain what Tessera is doing.